Related references
Note: Only part of the references are listed.Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring
Martin Andrs et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
Daniel L. Menezes et al.
MOLECULAR CANCER RESEARCH (2015)
Development of pharmacodynamic biomarkers for ATR inhibitors
Tao Chen et al.
MOLECULAR ONCOLOGY (2015)
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors
Paul A. Barsanti et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors
Paul A. Barsanti et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Identification of ATR-Chk1 Pathway Inhibitors That Selectively Target p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity
Masaoki Kawasumi et al.
CANCER RESEARCH (2014)
ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
Rozenn Josse et al.
CANCER RESEARCH (2014)
Targeting ATR in DNA damage response and cancer therapeutics
Emmanouil Fokas et al.
CANCER TREATMENT REVIEWS (2014)
ATM signalling and cancer
C. A. Cremona et al.
ONCOGENE (2014)
General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor
Frederick W. Goldberg et al.
TETRAHEDRON (2014)
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Amy B. Hall et al.
ONCOTARGET (2014)
Sulfoximines: A Neglected Opportunity in Medicinal Chemistry
Ulrich Luecking
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Qingsong Liu et al.
CANCER RESEARCH (2013)
The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the Treatment of Cancer
Ulrich Luecking et al.
CHEMMEDCHEM (2013)
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
Kevin M. Foote et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Yosef Shiloh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family
M. Raymond V. Finlay et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor
M. Raymond V. Finlay et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
Remko Prevo et al.
CANCER BIOLOGY & THERAPY (2012)
Targeting the S and G2 checkpoint to treat cancer
Tao Chen et al.
DRUG DISCOVERY TODAY (2012)
Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines
Stefan Berg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
AIR signalling: more than meeting at the fork
Edward A. Nam et al.
BIOCHEMICAL JOURNAL (2011)
Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery
James R. Brown et al.
BMC EVOLUTIONARY BIOLOGY (2011)
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
A. Peasland et al.
BRITISH JOURNAL OF CANCER (2011)
Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Raparnycin (mTOR) Inhibitor for Treatment of Cancer
Qingsong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
Jean-Damien Charrier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Philip M. Reaper et al.
NATURE CHEMICAL BIOLOGY (2011)
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Matilde Murga et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators
Donna M. Huryn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
Oren Gilad et al.
CANCER RESEARCH (2010)
The DNA-dependent protein kinase (DNA-PK) More than just a case of making ends meet?
Richard Hill et al.
CELL CYCLE (2010)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
Hiroshi Nishida et al.
NUCLEIC ACIDS RESEARCH (2009)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
ATR: an essential regulator of genome integrity
Karlene A. Cimprich et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Small molecule-based reversible reprogramming of cellular lifespan
Jaejoon Won et al.
NATURE CHEMICAL BIOLOGY (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Chemistry and biology of wortmannin
P Wipf et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2005)
Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway
GK Alderton et al.
HUMAN MOLECULAR GENETICS (2004)
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints
A Sancar et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
Cell cycle checkpoint signaling through the ATM and ATR kinases
RT Abraham
GENES & DEVELOPMENT (2001)
DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?
D Durocher et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
CE Arris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
